Please login to the form below

Not currently logged in
Email:
Password:

Seroxat

This page shows the latest Seroxat news and features for those working in and with pharma, biotech and healthcare.

UK government fines GSK over 'pay-for-delay' deals

UK government fines GSK over 'pay-for-delay' deals

The UK's Competition &Markets Authority has fined GlaxoSmithKline (GSK) and several other companies for delaying the availability of generic versions of its antidepressant Seroxat. ... The CMA's decision relates to activities between 2001 and 2004 in

Latest news

  • GSK holds on to older products GSK holds on to older products

    £185m. Other products in GSK's established portfolio with declining sales include antidepressant Seroxat/Paxil (paroxetine) and antiviral drug Valtrex (valacyclovir), both of which had a double digit fall in revenues

  • GSK plans to sell off older products GSK plans to sell off older products

    Imitrex (sumatriptan) for migraine, the antidepressant Paxil/Seroxat (paroxetine) and gastrointestinal therapy Zantac (ranitidine) have all been named in dispatches as former blockbuster brands that are now in GSK's 'established

  • Hisamitsu's Noven unit signs Brisdelle deal with Shionogi Hisamitsu's Noven unit signs Brisdelle deal with Shionogi

    Brisdelle contains 7.5mg of paroxetine, which - at a slightly higher dose - is the active ingredient in antidepressants like GlaxoSmithKline's now off-patent Seroxat/Paxil. ... In common with Seroxat Brisdelle also carries a Boxed Warning about

  • This month in 2000: The formation of GSK This month in 2000: The formation of GSK

    Since then, GSK has been consistently one of the world's best-performing healthcare companies, led by such prescription drugs as asthma treatment Advair/Seretide (fluticasone/salmeterol) and the antidepressant

  • Pay-for-delay deals lead to inflated drug prices says study Pay-for-delay deals lead to inflated drug prices says study

    Of these companies, Lundbeck is facing a penalty of 240m. Meanwhile, the UK Office of Fair Trading has accused GlaxoSmithKline of blocking the entry of generic versions of its Seroxat (paroxetine)

More from news
Approximately 3 fully matching, plus 26 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics